Something went wrong

We encountered an unexpected error, we encourage you to try again later.

We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

PP-UNP-USA-5796
Order samples Unable to confirm your eligibility

Unfortunately, your registration is incomplete and we are unable to confirm your eligibility for sample ordering.

To gain access please enter your professional information within your account.

Open your account We're here to help

Should you need further support updating your account information, please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

​​​​​​​PP-UNP-USA-5796
Order samples
Thank you for expressing interest in Pfizer samples. Currently there are no samples available to order. Samples renew periodically, we encourage you to check back soon.
 We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

​​​​​​​PP-UNP-USA-5796
Order samples

All samples available online to you are included below. Availability is updated periodically.

PP-UNP-USA-5796
Important Notice

Savings cards will be shipped with Product Samples, if applicable.

Signature

Use your mouse, finger, or stylus to sign below.

Legal Notice

I certify that I am a licensed prescriber, eligible to request and receive the drug samples listed in the quantities indicated. I am also confirming that these samples will be used exclusively for the medical treatment of my patients in conformity with all relevant state and/or local prescribing and dispensing requirements. My signature will also serve as confirmation of my receipt of these medications, if delivered by a company representative, or my intention to acknowledge them upon delivery to my medical office if shipped via common carrier. I understand that these samples cannot be sold, traded, bartered returned for credit or utilized to seek or obtain reimbursement.

Your order has been placed

We have received your order and are getting it ready

More to explore Patient assistance

Download available co-pay cards and patient savings offers across select Pfizer products.

Explore patient assistance Loading Vaccines

Find out more about the diseases, treatments and prevention methods that are impacted by our Pfizer Vaccine portfolio.

Explore Vaccines Loading
PP-UNP-USA-5796
Leave ordering?

Changes you have made will not be saved.

This site is intended for U.S. healthcare professionals.

For patient resources and support click HERE

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

HomeDisease EducationDisease
EducationDisease EducationDisparitiesEfficacy and SafetyEfficacy and SafetyImmunogenicitySafetyDosing and AdministrationDosing and
AdministrationDosing RecommendationsAdministrationResourcesResourcesOrdering PENBRAYARequest a Representative MaterialsVideos
Prescribing InformationIndicationsTRUMENBARequest a RepLoading
The realities of adolescent life put them at higher risk for meningococcal disease Social behaviors are largely responsible for the meningococcal carriage increase observed in adolescents and young adults1: Sharing drinks/food2
  • Sports teams
  • Extracurricular activities/clubs
 Sharing drinks/food2 Sharing drinks/food2
  • Sports teams
  • Extracurricular activities/clubs
Intimacy3
  • Kissing
Smoking/vaping4 Attending parties3 Living in close quarters3
  • Sleepaway camps
  • Boarding schools
  • Dorm living
  • Military barracks
Although meningococcal disease is a threat* to adolescents and young adults, vaccine completion rates† remain low5-8
Scroll left to view table
Although 61% of adolescents and young adults complete their MenACWY series, the majority do not get their second MenB dose.8

68% of meningococcal disease cases in 16- to 23-year-olds are caused by MenB5-7‡

MenB disproportionately affects older adolescents and young adults compared with other vaccine-preventable serogroups5-7‡

 Ensure that your older adolescent and young adult patients are fully vaccinated with 2 doses of a MenB-containing vaccine9ReferencesAmong adolescents and young adults, those 16 through 23 years have the highest rates of meningococcal disease.7 Based on the 2024 National Immunization Survey of 13- to 17-year-olds in the United States, coverage rates among 17-year-olds for MenACWY were 91.9% for Dose 1 and 61.1% for Dose 2 (n=3139). For MenB coverage, 36.9% received Dose 1 and 15.9% received Dose 2 (n=3139). MenACWY ≥2 doses calculated only among adolescents aged 17 years at time of interview; does not include adolescents who received their first dose of MenACWY at age ≥16 years. The average completion rate of ≥1 dose of MenACWY for 13- to 17-year-olds was 90.1% (n=16,325). MenB ≥1 dose calculated only among adolescents aged 17 years at time of interview, with vaccine administered based on shared clinical decision-making.8Data from CDC Meningococcal Surveillance Report 2022-2023. Cumulative data for 16-23 age range-2022: B=17, C=8, W=0, Y=0, A=0. Total=25; 2023, B=11, C=0, W=0, Y=5, A=0. Total=16; 2022+2023: B=28, C=8, W=0, Y=5, A=0. Total=41.5,6 Meningococcal disease, while uncommon, is serious and can progress quickly10-1224 hrs24 hrs

death can occur in as little as 24 hours from first symptoms10,12,13

1 in 101 in 10

cases of meningococcal disease will result in death, even with prompt antibiotic treatment13

1 in 5 survivors1 in 5 survivors

have long-term effects that may last a lifetime, such as hearing loss, vision loss, brain damage, and amputation13,14

Nearly 25% of adolescents and young adults may be meningococcal bacteria carriers, and can spread disease at any time without showing symptoms15,16§
  • Older adolescents and young adults are at higher risk for meningococcal disease, which can strike at any time7,12,15,16
  • Cases and outbreaks of meningococcal disease can occur in otherwise healthy individuals with sudden onset12
ReferencesN. meningitidis can colonize the nasopharynx of individuals without causing symptoms (carriage) and is transmitted through close contact. Bacteria transmitted by carrier individuals can unpredictably become symptomatic.15In 2024, US meningococcal disease cases reached their highest level (522 reported cases) since 2013 and remained elevated in 2025, with 463 confirmed and probable cases reported—the second highest since 20135,6,17-27¶#ReferencesCDC surveillance data are observational data only, based on incidence rates from 2013 through 2025 collected through the NNDSS run by the CDC. The number of cases for reporting years 2013 to 2023 were as follows: 2013=556; 2014=426; 2015=359; 2016=372; 2017=350; 2018=329; 2019=375; 2020=235; 2021=209; 2022=309; 2023=437.5,6,17-27Data reported in 2024 and 2025 are provisional and subject to change.CDC=Centers for Disease Control and Prevention; NNDSS=National Notifiable Diseases Surveillance System.References:Harrison LH, Granoff OM, Pollard AJ. Meningococcal capsular group A, C, W, and Y conjugate vaccines. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM, eds. Plotkin's Vaccines. 7th ed. Chapter 38. Philadelphia, PA: Elsevier Inc; 2018:619-643.e11.Davies HD, Jackson MA, Rice SG. American Academy of Pediatrics. Committee on Infectious Diseases, Council on Sports Medicine and Fitness. Clinical report: infectious diseases associated with organized sports and outbreak control. Pediatrics. 2017;140(4):e20172477.Burman C, Serra L, Nuttens C, Presa J, Balmer P, York L. Meningococcal disease in adolescents and young adults: a review of the rationale for prevention through vaccination. Hum Vaccin Immunother. 2019;15(2):459-469.Arnold FW, Parrish LW, Marimuthu S, et al. Meningococcal carriage and transmission dynamics in college students in Louisville, Kentucky. PLoS One. 2026;21(3):e0344194.Centers for Disease Control and Prevention. Enhanced meningococcal disease surveillance report, 2022: confirmed and probable cases reported to the National Notifiable Diseases Surveillance System, 2022. Updated April 8, 2024. Accessed June 8, 2026. https://www.cdc.gov/meningococcal/downloads/ncird-ems-report-2022-508.pdfCenters for Disease Control and Prevention. Enhanced meningococcal disease surveillance report, 2023: confirmed and probable cases reported to the National Notifiable Diseases Surveillance System, 2023. Updated March 21, 2025. Accessed June 8, 2026. https://www.cdc.gov/meningococcal/media/pdfs/2025/04/NCIRD-EMDS-Report-2023_508.pdfCenters for Disease Control and Prevention. Meningococcal disease surveillance and trends. Updated June 4, 2026. Accessed July 30, 2026. https://www.cdc.gov/meningococcal/php/surveillance/index.htmlPingali C, Yankey D, Elam-Evans LD, et al. National vaccination coverage among adolescents 13-17 years—National Immunization Survey–Teen, United States, 2024. MMWR Morb Mortal Wkly Rep. 2025;74(30):466-473.Collins JP, Crowe SJ, Ortega-Sanchez IR, et al. Use of the Pfizer pentavalent meningococcal vaccine among persons aged ≥10 years: recommendations of the Advisory Committee on Immunization Practices—United States, 2023. MMWR Morb Mortal Wkly Rep. 2024;73(15):345-350.Thompson MJ, Ninis N, Perera R, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367(9508):397-403.Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998–2007: implications for prevention of meningococcal disease. Clin Infect Dis. 2010;50(2):184-191.Centers for Disease Control and Prevention. About meningococcal disease. Updated March 30, 2026. Accessed May 28, 2026. https://www.cdc.gov/meningococcal/about/index.htmlCenters for Disease Control and Prevention. Meningococcal disease symptoms and complications. Updated March 6, 2026. Accessed May 22, 2026. https://www.cdc.gov/meningococcal/symptoms/index.htmlWorld Health Organization. Meningitis. Updated April 1, 2025. Accessed May 26, 2026. https://www.who.int/news-room/fact-sheets/detail/meningitisYazdankhah SP, Caugant DA. Neisseria meningitidis: an overview of the carriage state. J Med Microbiol. 2004;53(Pt 9):821-832.Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(12):853-861.Centers for Disease Control and Prevention. Active bacterial core surveillance report, Emerging Infections Program Network, Neisseria meningitidis, 2024. Updated March 23, 2026. Accessed July 23, 2026. https://www.cdc.gov/abcs/bact-facts/data-dashboard.htmlCenters for Disease Control and Prevention. Meningococcal disease surveillance and trends. Updated June 4, 2026. Accessed July 23, 2026. https://www.cdc.gov/meningococcal/php/surveillance/index.html Centers for Disease Control and Prevention. Active bacterial core surveillance report, Emerging Infections Program Network, Neisseria meningitidis, 2013. Updated March 24, 2015. Accessed July 23, 2026. https://stacks.cdc.gov/view/cdc/41408Centers for Disease Control and Prevention. Active bacterial core surveillance report, Emerging Infections Program Network, Neisseria meningitidis, 2014. Updated April 25, 2016. Accessed July 23, 2026. https://stacks.cdc.gov/view/cdc/39906Centers for Disease Control and Prevention. Enhanced meningococcal disease surveillance report, 2015: confirmed and probable cases reported to the National Notifiable Diseases Surveillance System, 2015. Updated September 1, 2017. Accessed July 23, 2026. https://stacks.cdc.gov/view/cdc/140463Centers for Disease Control and Prevention. Enhanced meningococcal disease surveillance report, 2016: confirmed and probable cases reported to the National Notifiable Diseases Surveillance System, 2016. Published September 1, 2017. Accessed July 23, 2026. https://stacks.cdc.gov/view/cdc/49452Centers for Disease Control and Prevention. Enhanced meningococcal disease surveillance report, 2017: confirmed and probable cases reported to the National Notifiable Diseases Surveillance System, 2017. Published September 1, 2019. Accessed July 23, 2026. https://stacks.cdc.gov/view/cdc/140464Centers for Disease Control and Prevention. Enhanced meningococcal disease surveillance report, 2018: confirmed and probable cases reported to the National Notifiable Diseases Surveillance System, 2018. Updated October 7, 2019. Accessed July 23, 2026. https://stacks.cdc.gov/view/cdc/111348Centers for Disease Control and Prevention. Enhanced meningococcal disease surveillance report, 2019: confirmed and probable cases reported to the National Notifiable Diseases Surveillance System, 2019. Updated May 11, 2023. Accessed July 23, 2026. https://www.cdc.gov/meningococcal/downloads/ncird-ems-report-2019.pdfCenters for Disease Control and Prevention. Enhanced meningococcal disease surveillance report, 2020: confirmed and probable cases reported to the National Notifiable Diseases Surveillance System, 2020. Updated May 11, 2023. Accessed July 23, 2026. https://www.cdc.gov/meningococcal/downloads/ncird-ems-report-2020.pdfCenters for Disease Control and Prevention. Enhanced meningococcal disease surveillance report, 2021: confirmed and probable cases reported to the National Notifiable Diseases Surveillance System, 2021. Updated June 21, 2023. Accessed July 23, 2026. https://www.cdc.gov/meningococcal/downloads/ncird-ems-report-2021.pdfPENBRAYA® (Meningococcal Groups A, B, C, W, and Y Vaccine). Prescribing information. Pfizer Inc.; 2026.

Disease EducationKicker Simplified dosing

Complete the meningococcal disease vaccine schedule in one less dose.9

 See dosing LoadingKicker Demonstrated immunogenicity

PENBRAYA has demonstrated robust immunogenicity against all 5 vaccine-preventable meningococcal serogroups (MenA, B, C, W, and Y).28

 See immunogenicity Loading

To report an adverse event, please call 1‑800‑438‑1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2026 Pfizer Inc. All rights reserved.

PP-PBI-USA-0552
You are now leaving Pfizer You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. 

PP-MCL-USA-0367
Indications
  • PENBRAYA is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y. PENBRAYA is approved for use in individuals 10 through 25 years of age
  • TRUMENBA is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. TRUMENBA is approved for use in individuals 10 through 25 years of age 
Important Safety Information
  • Do not administer PENBRAYA or TRUMENBA to individuals with a history of severe allergic reaction (eg, anaphylaxis) to any component of PENBRAYA or TRUMENBA. Appropriate medical treatment used to manage allergic reactions must be available in the event an anaphylactic reaction occurs immediately following administration of PENBRAYA or TRUMENBA
  • Syncope (fainting) may occur in association with administration of injectable vaccines, including PENBRAYA or TRUMENBA. Procedures should be in place to avoid injury from fainting
  • Some individuals with altered immunocompetence may have reduced immune responses to PENBRAYA or TRUMENBA
  • Individuals with certain complement deficiencies and individuals receiving treatment that inhibits terminal complement activation are at increased risk for invasive disease caused by N. meningitidis groups A, B, C, W, and Y, even if they develop antibodies following vaccination with PENBRAYA
  • Individuals with certain complement deficiencies and individuals receiving treatment that inhibits terminal complement activation are at increased risk for invasive disease caused by N. meningitidis group B, even if they develop antibodies following vaccination with TRUMENBA
  • Vaccination with PENBRAYA or TRUMENBA may not protect all vaccine recipients
  • Vaccination with PENBRAYA does not substitute for vaccination with a tetanus toxoid–containing vaccine to prevent tetanus
  • Guillain-Barré syndrome (GBS) has been reported in temporal relationship following administration of another US-licensed meningococcal quadrivalent polysaccharide conjugate vaccine. The decision by the healthcare professional to administer PENBRAYA to individuals with a history of GBS should take into account the expected benefits and potential risks 
  • For PENBRAYA, the most commonly reported (≥15%) solicited adverse reactions after Dose 1 and Dose 2, respectively, were pain at the injection site (89% and 84%), fatigue (52% and 48%), headache (47% and 40%), muscle pain (26% and 23%), injection site redness (26% and 23%), injection site swelling (25% and 24%), joint pain (20% and 18%), and chills (20% and 16%)
  • For TRUMENBA, the most common solicited adverse reactions in adolescents and young adults were pain at injection site (≥85%), fatigue (≥60%), headache (≥55%), and muscle pain (≥35%)
  • Data are not available on the safety and effectiveness of using TRUMENBA and other meningococcal group B vaccines interchangeably to complete the vaccination series
  • The safety and effectiveness of PENBRAYA or TRUMENBA have not been established in pregnant individuals
Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Please see full Prescribing Information for PENBRAYA and full Prescribing Information for TRUMENBA.Indications
  • PENBRAYA is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y. PENBRAYA is approved for use in individuals 10 through 25 years of age
  • TRUMENBA is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. TRUMENBA is approved for use in individuals 10 through 25 years of age